1
|
Krishnan HS, Bernard-Gauthier V, Placzek MS, Dahl K, Narayanaswami V, Livni E, Chen Z, Yang J, Collier TL, Ran C, Hooker JM, Liang SH, Vasdev N. Metal Protein-Attenuating Compound for PET Neuroimaging: Synthesis and Preclinical Evaluation of [11C]PBT2. Mol Pharm 2018; 15:695-702. [DOI: 10.1021/acs.molpharmaceut.7b00936] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/20/2023]
Affiliation(s)
- Hema S. Krishnan
- Division
of Nuclear Medicine and Molecular Imaging, Massachusetts General Hospital, Boston, Massachusetts 02114, United States
- Department
of Radiology, Harvard Medical School, Boston, Massachusetts 02115, United States
| | - Vadim Bernard-Gauthier
- Division
of Nuclear Medicine and Molecular Imaging, Massachusetts General Hospital, Boston, Massachusetts 02114, United States
- Department
of Radiology, Harvard Medical School, Boston, Massachusetts 02115, United States
| | - Michael S. Placzek
- Department
of Radiology, Harvard Medical School, Boston, Massachusetts 02115, United States
- Athinoula A. Martinos Center for Biomedical Imaging, Massachusetts General Hospital, Charlestown, Massachusetts 02129, United States
| | - Kenneth Dahl
- Division
of Nuclear Medicine and Molecular Imaging, Massachusetts General Hospital, Boston, Massachusetts 02114, United States
- Department
of Radiology, Harvard Medical School, Boston, Massachusetts 02115, United States
| | - Vidya Narayanaswami
- Division
of Nuclear Medicine and Molecular Imaging, Massachusetts General Hospital, Boston, Massachusetts 02114, United States
| | - Elijahu Livni
- Division
of Nuclear Medicine and Molecular Imaging, Massachusetts General Hospital, Boston, Massachusetts 02114, United States
- Department
of Radiology, Harvard Medical School, Boston, Massachusetts 02115, United States
| | - Zhen Chen
- Division
of Nuclear Medicine and Molecular Imaging, Massachusetts General Hospital, Boston, Massachusetts 02114, United States
| | - Jing Yang
- Department
of Radiology, Harvard Medical School, Boston, Massachusetts 02115, United States
- Athinoula A. Martinos Center for Biomedical Imaging, Massachusetts General Hospital, Charlestown, Massachusetts 02129, United States
| | - Thomas L. Collier
- Division
of Nuclear Medicine and Molecular Imaging, Massachusetts General Hospital, Boston, Massachusetts 02114, United States
- Department
of Radiology, Harvard Medical School, Boston, Massachusetts 02115, United States
- Research
and Development, Advion Inc., Ithaca, New York 14850, United States
| | - Chongzhao Ran
- Department
of Radiology, Harvard Medical School, Boston, Massachusetts 02115, United States
- Athinoula A. Martinos Center for Biomedical Imaging, Massachusetts General Hospital, Charlestown, Massachusetts 02129, United States
| | - Jacob M. Hooker
- Department
of Radiology, Harvard Medical School, Boston, Massachusetts 02115, United States
- Athinoula A. Martinos Center for Biomedical Imaging, Massachusetts General Hospital, Charlestown, Massachusetts 02129, United States
| | - Steven H. Liang
- Division
of Nuclear Medicine and Molecular Imaging, Massachusetts General Hospital, Boston, Massachusetts 02114, United States
- Department
of Radiology, Harvard Medical School, Boston, Massachusetts 02115, United States
| | - Neil Vasdev
- Division
of Nuclear Medicine and Molecular Imaging, Massachusetts General Hospital, Boston, Massachusetts 02114, United States
- Department
of Radiology, Harvard Medical School, Boston, Massachusetts 02115, United States
| |
Collapse
|
2
|
Munekane M, Ueda M, Motomura S, Kamino S, Haba H, Yoshikawa Y, Yasui H, Enomoto S. Investigation of Biodistribution and Speciation Changes of Orally Administered Dual Radiolabeled Complex, Bis(5-chloro-7-[ 131I]iodo-8-quinolinolato)[ 65Zn]zinc. Biol Pharm Bull 2017; 40:510-515. [PMID: 28381805 DOI: 10.1248/bpb.b16-00945] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Abstract
Many zinc (Zn) complexes have been developed as promising oral antidiabetic agents. In vitro assays using adipocytes have demonstrated that the coordination structures of Zn complexes affect the uptake of Zn into cells and have insulinomimetic activities, for which moderate stability of Zn complexes is vital. The complexation of Zn plays a major role improving its bioavailability. However, investigation of the speciation changes of Zn complexes after oral administration is lacking. A dual radiolabeling approach was applied in order to investigate the speciation of bis(5-chloro-7-iodo-8-quinolinolato)zinc complex [Zn(Cq)2], which exhibits the antidiabetic activity in diabetic mice. In the present study, 65Zn- and 131I-labeled [Zn(Cq)2] were synthesized, and their biodistribution were analyzed after an oral administration using both invasive conventional assays and noninvasive gamma-ray emission imaging (GREI), a novel nuclear medicine imaging modality that enables analysis of multiple radionuclides simultaneously. The GREI experiments visualized the behavior of 65Zn and [131I]Cq from the stomach to large intestine and through the small intestine; most of the administered Zn was transported together with clioquinol (5-chloro-7-iodo-8-quinolinol) (Cq). Higher accumulation of 65Zn for [Zn(Cq)2] than ZnCl2 suggests that the Zn associated with Cq was highly absorbed by the intestinal tract. In particular, the molar ratio of administered iodine to Zn decreased during the distribution processes, indicating the dissociation of most [Zn(Cq)2] complexes. In conclusion, the present study successfully evaluated the speciation changes of orally administered [Zn(Cq)2] using the dual radiolabeling method.
Collapse
Affiliation(s)
- Masayuki Munekane
- Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama University
| | | | | | | | | | | | | | | |
Collapse
|
3
|
Liang SH, Southon AG, Fraser BH, Krause-Heuer AM, Zhang B, Shoup TM, Lewis R, Volitakis I, Han Y, Greguric I, Bush AI, Vasdev N. Novel Fluorinated 8-Hydroxyquinoline Based Metal Ionophores for Exploring the Metal Hypothesis of Alzheimer's Disease. ACS Med Chem Lett 2015; 6:1025-9. [PMID: 26396692 DOI: 10.1021/acsmedchemlett.5b00281] [Citation(s) in RCA: 37] [Impact Index Per Article: 4.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/11/2015] [Accepted: 08/09/2015] [Indexed: 12/14/2022] Open
Abstract
Zinc, copper, and iron ions are involved in amyloid-beta (Aβ) deposition and stabilization in Alzheimer's disease (AD). Consequently, metal binding agents that prevent metal-Aβ interaction and lead to the dissolution of Aβ deposits have become well sought therapeutic and diagnostic targets. However, direct intervention between diseases and metal abnormalities has been challenging and is partially attributed to the lack of a suitable agent to determine and modify metal concentration and distribution in vivo. In the search of metal ionophores, we have identified several promising chemical entities by strategic fluorination of 8-hydroxyquinoline drugs, clioquinol, and PBT2. Compounds 15-17 and 28-30 showed exceptional metal ionophore ability (6-40-fold increase of copper uptake and >2-fold increase of zinc uptake) and inhibition of zinc induced Aβ oligomerization (EC50s < ∼5 μM). These compounds are suitable for further development as drug candidates and/or positron emission tomography (PET) biomarkers if radiolabeled with (18)F.
Collapse
Affiliation(s)
- Steven H. Liang
- Division
of Nuclear Medicine and Molecular Imaging, Massachusetts General Hospital, Boston, Massachusetts 02114, United States
- Department of Radiology, Harvard Medical School, Boston, Massachusetts 02115, United States
| | - Adam G. Southon
- Florey
Institute of Neuroscience and Mental Health, University of Melbourne, Parkville, Victoria 3010, Australia
| | - Benjamin H. Fraser
- Radiopharmaceutical
Research and Development, Life Sciences, Australian Nuclear Science and Technology Organisation, Kirrawee, New South Wales 2232, Australia
| | - Anwen M. Krause-Heuer
- Radiopharmaceutical
Research and Development, Life Sciences, Australian Nuclear Science and Technology Organisation, Kirrawee, New South Wales 2232, Australia
| | - Bo Zhang
- Radiopharmaceutical
Research and Development, Life Sciences, Australian Nuclear Science and Technology Organisation, Kirrawee, New South Wales 2232, Australia
| | - Timothy M. Shoup
- Division
of Nuclear Medicine and Molecular Imaging, Massachusetts General Hospital, Boston, Massachusetts 02114, United States
- Department of Radiology, Harvard Medical School, Boston, Massachusetts 02115, United States
| | - Rebecca Lewis
- Division
of Nuclear Medicine and Molecular Imaging, Massachusetts General Hospital, Boston, Massachusetts 02114, United States
| | - Irene Volitakis
- Florey
Institute of Neuroscience and Mental Health, University of Melbourne, Parkville, Victoria 3010, Australia
| | - Yifeng Han
- The
Key Laboratory of Advanced Textile Materials and Manufacturing Technology,
Department of Chemistry, Zhejiang Sci-Tech University, Hangzhou 310018, China
| | - Ivan Greguric
- Radiopharmaceutical
Research and Development, Life Sciences, Australian Nuclear Science and Technology Organisation, Kirrawee, New South Wales 2232, Australia
| | - Ashley I. Bush
- Florey
Institute of Neuroscience and Mental Health, University of Melbourne, Parkville, Victoria 3010, Australia
| | - Neil Vasdev
- Division
of Nuclear Medicine and Molecular Imaging, Massachusetts General Hospital, Boston, Massachusetts 02114, United States
- Department of Radiology, Harvard Medical School, Boston, Massachusetts 02115, United States
| |
Collapse
|
4
|
Liang SH, Holland JP, Stephenson NA, Kassenbrock A, Rotstein BH, Daignault CP, Lewis R, Collier L, Hooker JM, Vasdev N. PET neuroimaging studies of [(18)F]CABS13 in a double transgenic mouse model of Alzheimer's disease and nonhuman primates. ACS Chem Neurosci 2015; 6:535-41. [PMID: 25776827 DOI: 10.1021/acschemneuro.5b00055] [Citation(s) in RCA: 18] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/01/2023] Open
Abstract
Fluorine-18 labeled 2-fluoro-8-hydroxyquinoline ([(18)F]CABS13) is a promising positron emission tomography (PET) radiopharmaceutical based on a metal chelator developed to probe the "metal hypothesis of Alzheimer's disease". Herein, a practical radiosynthesis of [(18)F]CABS13 was achieved by radiofluorination followed by deprotection of an O-benzyloxymethyl group. Automated production and formulation of [(18)F]CABS13 resulted in 19 ± 5% uncorrected radiochemical yield, relative to starting [(18)F]fluoride, with ≥95% chemical and radiochemical purities, and high specific activity (>2.5 Ci/μmol) within 80 min. Temporal PET neuroimaging studies were carried out in female transgenic B6C3-Tg(APPswe,PSEN 1dE9)85Dbo/J (APP/PS1) and age-matched wild-type (WT) B6C3F1/J control mice at 3, 7, and 10 months of age. [(18)F]CABS13 showed an overall higher uptake and retention of radioactivity in the central nervous system of APP/PS1 mice versus WT mice with increasing age. However, PET/magnetic resonance imaging in normal nonhuman primates revealed that the tracer had low uptake in the brain and rapid formation of a hydrophilic radiometabolite. Identification of more metabolically stable (18)F-hydroxyquinolines that can be readily accessed by the radiochemical strategy presented herein is underway.
Collapse
Affiliation(s)
- Steven H. Liang
- Division of Nuclear Medicine and Molecular Imaging & Center for Advanced Medical Imaging Sciences, Massachusetts General Hospital, Boston, Massachusetts 02114, United States
- Department
of Radiology, Harvard Medical School, Boston, Massachusetts 02114, United States
| | - Jason P. Holland
- Department
of Radiology, Harvard Medical School, Boston, Massachusetts 02114, United States
| | - Nickeisha A. Stephenson
- Division of Nuclear Medicine and Molecular Imaging & Center for Advanced Medical Imaging Sciences, Massachusetts General Hospital, Boston, Massachusetts 02114, United States
- Department
of Radiology, Harvard Medical School, Boston, Massachusetts 02114, United States
| | - Alina Kassenbrock
- Division of Nuclear Medicine and Molecular Imaging & Center for Advanced Medical Imaging Sciences, Massachusetts General Hospital, Boston, Massachusetts 02114, United States
| | - Benjamin H. Rotstein
- Division of Nuclear Medicine and Molecular Imaging & Center for Advanced Medical Imaging Sciences, Massachusetts General Hospital, Boston, Massachusetts 02114, United States
- Department
of Radiology, Harvard Medical School, Boston, Massachusetts 02114, United States
| | - Cory P. Daignault
- Division of Nuclear Medicine and Molecular Imaging & Center for Advanced Medical Imaging Sciences, Massachusetts General Hospital, Boston, Massachusetts 02114, United States
| | - Rebecca Lewis
- Division of Nuclear Medicine and Molecular Imaging & Center for Advanced Medical Imaging Sciences, Massachusetts General Hospital, Boston, Massachusetts 02114, United States
| | - Lee Collier
- Division of Nuclear Medicine and Molecular Imaging & Center for Advanced Medical Imaging Sciences, Massachusetts General Hospital, Boston, Massachusetts 02114, United States
- Department
of Radiology, Harvard Medical School, Boston, Massachusetts 02114, United States
- Advion, Inc., Ithaca, New York 14850, United States
| | - Jacob M. Hooker
- Department
of Radiology, Harvard Medical School, Boston, Massachusetts 02114, United States
- Athinoula
A. Martinos Center for Biomedical Imaging, Massachusetts General Hospital, Charlestown, Massachusetts 02129, United States
| | - Neil Vasdev
- Division of Nuclear Medicine and Molecular Imaging & Center for Advanced Medical Imaging Sciences, Massachusetts General Hospital, Boston, Massachusetts 02114, United States
- Department
of Radiology, Harvard Medical School, Boston, Massachusetts 02114, United States
| |
Collapse
|
5
|
Holland JP, Liang SH, Rotstein BH, Collier TL, Stephenson NA, Greguric I, Vasdev N. Alternative approaches for PET radiotracer development in Alzheimer's disease: imaging beyond plaque. J Labelled Comp Radiopharm 2013; 57:323-31. [PMID: 24327420 DOI: 10.1002/jlcr.3158] [Citation(s) in RCA: 36] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/07/2013] [Accepted: 10/29/2013] [Indexed: 12/18/2022]
Abstract
Alzheimer's disease (AD) and related dementias show increasing clinical prevalence, yet our understanding of the etiology and pathobiology of disease-related neurodegeneration remains limited. In this regard, noninvasive imaging with radiotracers for positron emission tomography (PET) presents a unique tool for quantifying spatial and temporal changes in characteristic biological markers of brain disease and for assessing potential drug efficacy. PET radiotracers targeting different protein markers are being developed to address questions pertaining to the molecular and/or genetic heterogeneity of AD and related dementias. For example, radiotracers including [(11) C]-PiB and [(18) F]-AV-45 (Florbetapir) are being used to measure the density of Aβ-plaques in AD patients and to interrogate the biological mechanisms of disease initiation and progression. Our focus is on the development of novel PET imaging agents, targeting proteins beyond Aβ-plaques, which can be used to investigate the broader mechanism of AD pathogenesis. Here, we present the chemical basis of various radiotracers which show promise in preclinical or clinical studies for use in evaluating the phenotypic or biochemical characteristics of AD. Radiotracers for PET imaging neuroinflammation, metal ion association with Aβ-plaques, tau protein, cholinergic and cannabinoid receptors, and enzymes including glycogen-synthase kinase-3β and monoamine oxidase B amongst others, and their connection to AD are highlighted.
Collapse
Affiliation(s)
- Jason P Holland
- Division of Nuclear Medicine and Molecular Imaging, Massachusetts General Hospital, Department of Radiology, Harvard Medical School, 55 Fruit St., White 427, Boston, Massachusetts, 02114, USA; Life Sciences, Australian Nuclear Science and Technology Organisation, Kirrawee, New South Wales, 2232, Australia
| | | | | | | | | | | | | |
Collapse
|
6
|
Tavares AAS, Jobson NK, Dewar D, Sutherland A, Pimlott SL. Development of the radiosynthesis of high-specific-activity 123I-NKJ64. Nucl Med Biol 2011; 38:493-500. [PMID: 21531286 DOI: 10.1016/j.nucmedbio.2010.11.011] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/29/2010] [Revised: 10/15/2010] [Accepted: 11/04/2010] [Indexed: 11/28/2022]
Abstract
INTRODUCTION (123)I-NKJ64, a reboxetine analogue, is currently under development as a potential novel single photon emission computed tomography radiotracer for imaging the noradrenaline transporter in brain. This study describes the development of the radiosynthesis of (123)I-NKJ64, highlighting the advantages and disadvantages, pitfalls and solutions encountered while developing the final radiolabelling methodology. METHODS The synthesis of (123)I-NKJ64 was evaluated using an electrophilic iododestannylation method, where a Boc-protected trimethylstannyl precursor was radioiodinated using peracetic acid as an oxidant and deprotection was investigated using either trifluoroacetic acid (TFA) or 2 M hydrochloric acid (HCl). RESULTS Radioiodination of the Boc-protected trimethylstannyl precursor was achieved with an incorporation yield of 92±6%. Deprotection with 2 M HCl produced (123)I-NKJ64 with the highest radiochemical yield of 98.05±1.63% compared with 83.95±13.24% with TFA. However, the specific activity of the obtained (123)I-NKJ64 was lower when measured after using 2 M HCl (0.15±0.23 Ci/μmol) as the deprotecting agent in comparison to TFA (1.76±0.60 Ci/μmol). Further investigation of the 2 M HCl methodology found a by-product, identified as the deprotected proto-destannylated precursor, which co-eluted with (123)I-NKJ64 during the high-performance liquid chromatography (HPLC) purification. CONCLUSIONS The radiosynthesis of (123)I-NKJ64 was achieved with good isolated radiochemical yield of 68% and a high specific activity of 1.8 Ci/μmol. TFA was found to be the most suitable deprotecting agent, since 2 M HCl generated a by-product that could not be fully separated from (123)I-NKJ64 using the HPLC methodology investigated. This study highlights the importance of HPLC purification and accurate measurement of specific activity while developing new radiosynthesis methodologies.
Collapse
Affiliation(s)
- Adriana Alexandre S Tavares
- Institute of Neuroscience and Psychology, College of Medical, Veterinary and Life Sciences, University of Glasgow, G12 8QQ Glasgow, UK.
| | | | | | | | | |
Collapse
|
7
|
Abstract
AbstractThe known IODO-GEN™-method [1] was adapted for radiolabeling of humic and fulvic acids with131I. The water insoluble oxidizing agent 1,3,4,6tetrachloro-3α,6α-diphenylglycoluril (IODO-GEN™) forms an iodous ion species (I+), which undergoes an electrophilic I/H-substitution on aromatic moieties of the humic and fulvic acids. This method offers mild conditions with a lesser extent of oxidative alterations of the target molecule, accompanied by an easy handling due to the virtual water-insolubility of the oxidizing agent. The method was optimized and different techniques were tested for the purification of the radioiodinated humic material. The yield of the labeling procedure varies between 45 and 75% depending on the provenance of the humic material and the applied purification method. A specific activity up to 40 MBq/mg was achieved. Furthermore, the known inherent photo-susceptibility of the iodinated humic substance and the influence of reducing agents were verified. An additional release of131I up to 20% and up to 35%, respectively were observed.
Collapse
Affiliation(s)
| | - H. Kupsch
- Institute of Interdisciplinary Isotope Research, Leipzig, Deutschland
| |
Collapse
|
8
|
Everson Da Silva L, Teixieira De Sousa P, Carlos Joussef A. Investigation of Chemoselective Reaction of 2-Amino-8-hydroxyquinoline with Arylsulfonylchloride Derivatives. SYNTHETIC COMMUN 2009. [DOI: 10.1080/00397910802527730] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
Affiliation(s)
| | | | - Antonio Carlos Joussef
- b Department of Chemistry , Universidade Federal de Santa Catarina , Florianópolis, Brazil
| |
Collapse
|
9
|
|